Emily Letton | News Reporter

Articles and archive:

Analysis | Cell & Gene Therapy | Finance | Finished Product | Ingredients | Logistics | Manufacturing | Packaging | Pharmaceutical | Regulatory | Research & Development

Emily covers the ever-changing pharma landscape and innovative ingredients from the supplement sector, with particular interest in sports nutrition and the policies and regulations shaping the market

Emily Letton

Profile

Emily is the Scientific Reporter for Nutraceutical Business Review and Manufacturing Chemist. Emily has a background in Biomedical Science and Genetics and a Master’s degree in Journalism from Oxford Brookes University. When she’s not reporting on the latest news, you'll find her in a boat on the river.

 

Related content

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
MC EXCLUSIVE: MHRA on a mission to redefine UK gene therapy

MC EXCLUSIVE: MHRA on a mission to redefine UK gene therapy

The UK's medicines regulator is seeking industry input on a landmark overhaul of gene therapy medicinal product definitions — the first substantive update in more than two decades — as synthetic mRNA and CRISPR-based technologies outpace the legal framework designed to govern them
You need to be a subscriber to read this article.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
Britain's biotech potential (part I): world-class science, second-class support?

Britain's biotech potential (part I): world-class science, second-class support?

The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
From lab to patient: how Fujifilm Cellular Dynamics is scaling iPSC therapies towards commercialisation

From lab to patient: how Fujifilm Cellular Dynamics is scaling iPSC therapies towards commercialisation

As induced pluripotent stem cell therapies move closer to commercial reality, Fujifilm Cellular Dynamics' COO Delara Motlagh explains how manufacturers are navigating the complex journey from early-phase flexibility to scalable, regulatory-ready production
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Packaging
RFID and smart labels: a new frontier in pharma packaging

RFID and smart labels: a new frontier in pharma packaging

Smart RFID and NFC labels are moving beyond simple identification to enable real-time traceability, automated inventory management and enhanced patient safety, positioning advanced labelling as a strategic tool in pharmaceutical manufacturing and hospital supply chains
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
US mRNA policy shift: are vaccine headwinds accelerating oncology focus?

US mRNA policy shift: are vaccine headwinds accelerating oncology focus?

With Washington’s stance on mRNA vaccines cooling, Manufacturing Chemist examines whether policy and funding signals could influence the pharmaceutical industry’s most commercially promising frontier: oncology therapeutics
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages

From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages

An EU-level stockpile may work, but only if it’s flexible, closely monitored and built with logistics in mind. Industry players say drug security will depend less on volume and more on data, digital oversight and early collaboration throughout the supply chain
Finance
Eli Lilly becomes first $1 trillion pharma company

Eli Lilly becomes first $1 trillion pharma company

Fuelled by the GLP-1 boom, the drugmaker's stock has surged by more than 35% this year, with the company reaching a $1 trillion valuation on Friday — becoming the first pharmaceutical company ever to achieve the milestone
Manufacturing
UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap?

UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap?

Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
Finance
Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion